Bone marrow toxicities in ovarian cancer patients treated with parp inhibitors
Introduction and aim of the study: PARP inhibitors (olaparib, niraparib) significantly improve the prognosis of patients with ovarian cancer. We aimed to analyze the hematological side effects of the patients treated with olaparib and niraparib.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Miko łaj Zaborowski, Cezary Miedziarek, Aleksandra Gładych-Macioszek, Ewa Nowak-Markwitz Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Hematology | OBGYN | Ovarian Cancer | Ovaries | Study | Toxicology